News und Analysen

Shares of Apellis Pharmaceuticals (NASDAQ: APLS) were down more than 9% on Wednesday, after falling as much as 12% earlier in the day. The company's shares fell following a short-seller report on

When a company that's increased its dividend annually since its initial public offering announces that it's planning to cut the payment, you know something big is going on. That's exactly what's

Fool.com contributor Parkev Tatevosian considers Invitae (NYSE: NVTA) stock and its financial prospects to determine if investors should buy the stock.

*Stock prices used were the afternoon prices

Last year was challenging for the stock market. Things have been better since 2023 started, but some equities have even performed pretty well throughout this ordeal. That's the case with Exelixis

Since December 2021, superstar investor Cathie Wood has been adding to her position in genetic-testing company Invitae (NYSE: NVTA) while many investors were doing just the opposite. The stock has

Inflation is giving investors more of an incentive to find ways to increase their income. If you have a decent nest egg saved up, you can use it to invest in dividend stocks to improve your

Shares of Neogen Corporation (NASDAQ: NEOG) were down more than 16% for the week, according to data provided by S&P Global Market Intelligence. The healthcare company, which specializes in food and

Shares of Insulet (NASDAQ: PODD) were sinking 9.3% as of 11:27 a.m. ET on Thursday after falling as much as 11.6% earlier in the session. The decline came as investors worried about the potential